These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1804932)

  • 41. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
    Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
    Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.
    Peebles RS; Sheller JR; Collins RD; Jarzecka K; Mitchell DB; Graham BS
    J Infect Dis; 2000 Sep; 182(3):671-7. PubMed ID: 10950758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.
    Crowe JE; Firestone CY; Murphy BR
    J Immunol; 2001 Oct; 167(7):3910-8. PubMed ID: 11564809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection.
    Wagner DK; Graham BS; Wright PF; Walsh EE; Kim HW; Reimer CB; Nelson DL; Chanock RM; Murphy BR
    J Clin Microbiol; 1986 Aug; 24(2):304-6. PubMed ID: 3755731
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes.
    Hu KF; Ekström J; Merza M; Lövgren-Bengtsson K; Morein B
    Med Microbiol Immunol; 1999 May; 187(4):191-8. PubMed ID: 10363675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice.
    Walsh EE
    Vaccine; 1993; 11(11):1135-8. PubMed ID: 8249433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
    Bian C; Liu S; Liu N; Zhang G; Xing L; Song Y; Duan Y; Gu H; Zhou Y; Zhang P; Li Z; Zhang K; Wang Z; Zhang S; Wang X; Yang P
    Antiviral Res; 2014 Apr; 104():110-7. PubMed ID: 24509239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential immunoglobulin G subclass antibody titers to respiratory syncytial virus F and G glycoproteins in adults.
    Wagner DK; Nelson DL; Walsh EE; Reimer CB; Henderson FW; Murphy BR
    J Clin Microbiol; 1987 Apr; 25(4):748-50. PubMed ID: 3571485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit.
    Oien NL; Brideau RJ; Walsh EE; Wathen MW
    Vaccine; 1994 Jun; 12(8):731-5. PubMed ID: 8091852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection.
    Weltzin R; Traina-Dorge V; Soike K; Zhang JY; Mack P; Soman G; Drabik G; Monath TP
    J Infect Dis; 1996 Aug; 174(2):256-61. PubMed ID: 8699052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication.
    Nicholas JA; Rubino KL; Levely ME; Meyer AL; Collins PL
    Virology; 1991 Jun; 182(2):664-72. PubMed ID: 2024493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.
    Johnson TR; Varga SM; Braciale TJ; Graham BS
    J Virol; 2004 Aug; 78(16):8753-60. PubMed ID: 15280483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.
    Plotnicky-Gilquin H; Robert A; Chevalet L; Haeuw JF; Beck A; Bonnefoy JY; Brandt C; Siegrist CA; Nguyen TN; Power UF
    J Virol; 2000 Apr; 74(8):3455-63. PubMed ID: 10729118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity.
    Oien NL; Brideau RJ; Thomsen DR; Homa FL; Wathen MW
    Vaccine; 1993; 11(10):1040-8. PubMed ID: 8212825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adenovirus vectored vaccines.
    Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
    Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.